OppHub America Desk · · Source: yahoo-tickers-tape-movers
Moderna Stock Reverses 20% Drop After Cancer Vaccine Trial Data
- Investors who participated in the initial surge in may be reviewing profit-taking strategies following the 20% intraday pullback. - 's trajectory is now partly linked to the potential success and market penetration of the joint cancer vaccine, alongside its existing Keytruda franchise.
Based on reporting from yahoo-tickers-tape-movers.
Moderna (MRNA) shares plummeted 20% on Thursday, a sharp reversal from their prior day's surge. The stock had previously rocketed 177% following positive Phase 3 trial results for an experimental cancer vaccine developed with Merck (MRK). Investors appear to be taking profits after the initial euphoria surrounding the vaccine's potential impact.
Market context for this story
As of: Regular HoursLoading quotes…
Informational only — not investment advice. Full markets →
$MRNAModerna
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/MRNA and related $MRK. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
Moderna (NASDAQ: MRNA) shares experienced a significant pullback, dropping 20% as of 12:00 PM ET on Thursday. This move follows an extraordinary 177% surge the previous day, which was driven by positive Phase 3 trial results for an mRNA cancer vaccine developed in partnership with Merck (NYSE: MRK). Merck's shares also saw a notable gain, rising 12.5% on the initial announcement.
The experimental vaccine, known as intismeran autogene (mRNA-4157), demonstrated a 49% reduction in the risk of recurrence or death compared to Keytruda alone in a Phase 2b trial for advanced melanoma. While the initial data sparked significant investor enthusiasm, the subsequent 20% decline suggests a profit-taking consolidation as the market assesses the broader commercial implications of this oncology platform. Moderna's year-to-date performance remains strong, showing a 369.03% increase.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
- Investors who participated in the initial surge in may be reviewing pr
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).